Stay updated on Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page’s displayed revision/version label has been incremented from v3.5.2 to v3.5.3, reflecting a release/version update rather than changes to trial content.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check42 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision tag updated to v3.4.3; the v3.4.2 tag was removed.SummaryDifference0.0%

- Check71 days agoChange DetectedAdded Overall Survival (OS) as an endpoint with follow-up up to 3 years and introduced multiple immune cell biomarkers (CD56, CD19, CD14, CD8, CD4, CD3, CD45) at various treatment-cycle timepoints. Removed prior CD8+ and CD3+ cell change endpoints measured at baseline and early post-treatment.SummaryDifference8%

- Check78 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-status notice and the prior Revision: v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.